| Literature DB >> 30909404 |
Yining Jin1, Harini G Acharya2, Devansh Acharya3, Rick Jorgensen4, Haoran Gao5, James Secord6, Perry K W Ng7, Venugopal Gangur8.
Abstract
The prevalence of wheat allergy has reached significant levels in many countries. Therefore, wheat is a major global food safety and public health issue. Animal models serve as critical tools to advance the understanding of the mechanisms of wheat allergenicity to develop preventive and control methods. A comprehensive review on the molecular mechanisms of wheat allergenicity using animal models is unavailable at present. There were two major objectives of this study: To identify the lessons that animal models have taught us regarding the molecular mechanisms of wheat allergenicity and to identify the strengths, challenges, and future prospects of animal models in basic and applied wheat allergy research. Using the PubMed and Google Scholar databases, we retrieved and critically analyzed the relevant articles and excluded celiac disease and non-celiac gluten sensitivity. Our analysis shows that animal models can provide insight into the IgE epitope structure of wheat allergens, effects of detergents and other chemicals on wheat allergenicity, and the role of genetics, microbiome, and food processing in wheat allergy. Although animal models have inherent limitations, they are critical to advance knowledge on the molecular mechanisms of wheat allergenicity. They can also serve as highly useful pre-clinical testing tools to develop safer genetically modified wheat, hypoallergenic wheat products, novel pharmaceuticals, and vaccines.Entities:
Keywords: IgE; animal model; food allergen; food allergy; food chemistry; food safety; molecular mechanisms; wheat allergenicity; wheat anaphylaxis; wheat hypersensitivity
Mesh:
Substances:
Year: 2019 PMID: 30909404 PMCID: PMC6471126 DOI: 10.3390/molecules24061142
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1The genesis of wheat allergy: sensitization and elicitation of disease. Development of wheat allergy involves two steps: Step-1: Exposure of genetically susceptible subject to wheat products via the eye, nasal, oral, and skin routes in the context of a dysregulated host-microbiome and additional environmental co-factors, such as detergents in facial soap containing wheat allergens, activate the T helper (Th)-2 immune responses with consequent IgE antibody production. These antibodies load the mast cells and basophils, resulting in the immune state termed as sensitization. Step-2: Re-exposure of sensitized subjects to wheat results in the binding of allergens to IgE-loaded mast cells and basophils that release histamine and other inflammatory mediators, causing clinical symptoms of disease (diarrhea, vomiting, hives, rashes, dermatitis, conjunctivitis, rhinitis, asthma, or anaphylaxis). In some cases, exercise after exposure to wheat can trigger anaphylaxis in sensitized subjects.
Figure 2Wheat allergens: effect of molecular modifications on wheat allergenicity in animal models. Wheat contains 10%–18% protein by a dry weight basis. The top part of the figure shows the relative composition of four groups of wheat protein allergens. These include gluten—alcohol-soluble gliadins (or prolamins) (30%–40%) and acetic acid or alkali-soluble glutenins (or glutelins) (45%–50%), and non-gluten proteins, such as water-soluble albumins (10%–12%) and saline-soluble globulins (5%–8%). The bottom part of the figure shows the effect of molecular changes induced by chemical and enzyme treatment on wheat protein allergenicity in animal models.
The dog and rat models of wheat allergy: experimental approaches used to study.
| Model/Developers | Wheat Protein Used | Sensitization (Route, Dose, Age, Gender, Adjuvant) | Elicitation of Reaction (Route, Dose and Age) | Immune Markers | Disease Phenotype |
|---|---|---|---|---|---|
| Wheat + cow’s milk + beef extract | SC injection (on days of age: days 1, 22, 29, 50, 57, 78, and 85) 1 ug each of the food allergens + 0.2 mL alum; SC injection distemper-hepatitis vaccine on days 21, 49, and 77; Booster at bimonthly intervals with 10 ug each of the food allergens; Bleedings at 3, 4 months | At 6 months: Feeding challenge with 200 g wheat flour gruel or cow’s milk | Specific IgE, Skin prick test | Vomiting and/or diarrhea (increased number of loose or watery stools for 2–4 days after the feeding challenge) | |
| Gluten (Unmodified, acid hydrolyzed, Enzyme hydrolyzed) Native gluten vs. acid hydrolyzed gluten | IP sensitization: day 0: 200 ug adsorbed on Alhydrogel/rat in PBS; Days 14, 21, and 28: 20 ug in 0.9% NaCl; 0.2 mL volume/bleeding on day 35 | None | Specific IgE, IgG Rat Basophilic Leukemia cell degranulation in vitro | None | |
| Oral sensitization: Female BN rats; Days 1 to 35: gavage with 0.2, 2, and 20 mg suspension in 0.5 mL PBS; Bleeding on days 0, 14, 28, and 42 | None | Specific IgE, IgG Rat Basophilic Leukemia cell degranulation in vitro | None | ||
| Skin sensitization: damage to skin then apply gluten without adjuvant 3 times per week for 3–5 weeks | None | Specific IgE, IgG antibodies | None |
IP = intra-peritoneal injection; SC = subcutaneous injection.
Wheat food allergy mouse models: experimental approaches.
| Model/Developers | Wheat Protein Used | Sensitization (Route, Dose, Age, Gender, Adjuvant) | Elicitation of Reaction (Route, Dose and Age) | Immune Markers | Disease Phenotype |
|---|---|---|---|---|---|
| Water/saline- soluble protein extract, Alcohol-soluble protein extract, alkali-soluble protein | IP (day 0, 14, 28, and 42) 10 ug + 1 mg alum/mouse Female B10.A | 20 mg/0.5 mL/mouse oral feeding plus acute or moderate exercise | Specific IgE | Time to exhaustion, mucosal lesions in the small intestine, wheat protein leakage into the liver | |
| Gliadin (Hardi) | IP (day 0, 10, 20, and 30) 10 or 20 ug + 1 mg alum/mouse 3-week females Balb/CJ 4–5-week females B10.A, C3H/HeJ | Nasal administration (10 ug on day 40) | Specific IgE, IgG1; IL-4, IL-5, IL-10, GM-CSF, IL-12 in lungs; cell counts in lung fluids | Eosinophil influx to lungs upon challenge | |
| Gliadin, purified ω5-gliadin | Gliadin 100 ug/mouse first IP injection; 50 ug/mouse for next 5 injections at weekly interval + 1 mg alum/mouse | Gliadin at 0.1 and 0.8 mg/mouse/0.5 mL acetic acid; ω5 gliadin at 0.1 mg/mouse/0.5 mL acetic acid | Specific IgE | Anaphylaxis by hypothermia shock response, voluntary exercise performance, leakage of wheat proteins into the blood | |
| Gliadins extract (Hardi) | IP (day 0, 10, 20, and 30) 10 ug of gliadins or LTP1 + 1 mg alum/mouse 3-week females | As in Bodinier et al. (2009) | Specific IgE | None reported | |
| Deamidated gliadins (acid hydrolysis) (Hardi) | IP (day 0, 10, 20, and 30) 10 ug + 1 mg alum/mouse, 6-week females | IP injection with 1 mg + 1 mg alum on day 38 | Total IgE, specific IgG1, IgG2a | None reported | |
| Acid hydrolyzed gluten | Skin sensitization (days 1–3, 8–10, 15–17, and 22–24) 0.5 mg | IP injection with 1 mg on days 18 or 25 | Specific IgE, IgG1, plasma histamine levels | Hypothermia shock response | |
| Native gliadin and deamidated gliadin by carboxylated cation exchange resin | IP (day 0, day 14) 50 ug of native gluten with 1 mg alum/mouse 5-week males | Intra-gastric administration of deamidated gliadin, 10 mg on days 28, 30, 32, 34, 36, 38, and 40 | Specific IgE; peritoneal mast cells, histamine (gut and plasma) | Intestinal permeability, mast cell degranulation | |
| Saline-soluble wheat protein (duram) | IP (days 0, 10, 24, and 40), 10 ug + 1 mg alum, 6–8-week females | IP injection with 0.5 mg, 1 week after last sensitization and repeated | Specific IgE, IgG1, total IgE murine mast cell protease-1, correlation analysis among readouts, cytokines, chemokines, adhesion molecule in skin lesion | Hypothermia shock response, atopic dermatitis, skin mast cell degranulation, mucosal mast cell mediator release |
IP = intraperitoneal injection; LTP = lipid transfer protein.
Pathogenic IgE binding peptide epitopes present in wheat identified using a mouse model.
| Protein | Pathogenic IgE Binding Peptide Epitopes |
|---|---|
|
| |
| LTP1 * | (1) QARSQSDRQS; (2) GIARGIHNLN |
|
| |
| α-gliadin | (1) PLVQQQ; (2) QQQFPGQQQQ #; (3) YLQLQLP #; (4) YPQQQPQYLQ; (5) SFQQPQQQYP |
| ω2-gliadin | (1) FPTPQQQFPE; (2) QQSFPLQPQQ #; (3) QQLFPELQ |
| ω5-gliadin | (1) QQFPQQQ #; (2) QQLPQQQ #; (3) QQSPQQQ #; (4) QQEFPQQQ; (5) QQQFPQQEFP |
* LTP1 = Lipid transfer protein 1. #: Epitope is present in both the human and mouse model; Amino acids: Q = Glutamine; I = Isoleucine; P = Proline; F = Phenylalanine; G = Glycine; S = Serine; Y = Tyrosine; L = Leucine; E = Glutamic Acid; V = Valine; R =Arginine; N = Asparagine. Reference: [29].
Major lessons learnt from animal models on wheat protein allergenicity.
| Species | Wheat Allergen | Exposure Route | Sensitization | Elicitation of Reaction | |
|---|---|---|---|---|---|
|
| Gliadins | IP | IgE | ND | |
| Glutenins |
| Oral | ND | Vomiting, Diarrhea | |
| Skin | ND | Skin Reaction | |||
| Thioredoxin Modified Gliadins & Glutenins | Skin | ND | Reduced Skin Reaction | ||
|
| Gliadins | IP | IgE | Anaphylaxis, EIA | |
| Gluten | Skin | No IgE | No Anaphylaxis | ||
| Gluten + Detergent | Skin | IgE | Anaphylaxis | ||
| Acid-Hydrolyzed gluten (AHG) | Skin | IgE | Anaphylaxis | ||
| AHG + Detergent | Skin | Increased IgE | Increased Anaphylaxis | ||
| Deamidated-Gliadins (DG) | IP | Increased IgE | ND | ||
| DG | Oral | ND | Reduced Gut Reactions | ||
| Albumins + Globulins | IP | IgE | Anaphylaxis | ||
| Dermatitis (Th1, Th2, Th17 Cytokines + Allergenic Chemokines) | |||||
|
| Gluten and AHG | IP | IgE | ND | |
| Skin | IgE | ND | |||
| Enzyme Hydrolyzed Gluten | Oral | IgE | ND | ||
| IP | IgE | ND | |||
| Oral | IgE | ND | |||
Abbreviations: IP = intraperitoneal injection; ND = not done; EIA = exercise-induced anaphylaxis.
Animal models of wheat allergy: relative strengths and limitations.
| Model Characteristics | Dog | Rat | Mouse |
|---|---|---|---|
|
| |||
| Protocol used in the model development is relatively simple | No | Yes | Yes |
| Used wheat flour for exposure | Yes | No | No |
| Used purified wheat allergens/extracts for exposure | No | Yes | Yes |
| Studied immune response to all four general groups of wheat allergens | Yes | No | No (most) |
| Used oral route to induce sensitization | No | Yes | No |
| Studied clinical reactions after oral exposure | Yes | No | No |
|
| |||
| Used adjuvant to induce sensitization | Yes | No | Yes |
| Used injection to induce sensitization | Yes | No | Yes |
| Used injection to elicit clinical reaction | Yes (skin) | No | Yes |
| Limited availability of animal breed/strain | Yes (Limited) | Commercially Available | Commercially Available |